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$300 billion will be spent in direct medical costs in these
six countries to treat smoking-related diseases over 20
years.
CONCLUSION: The model predictions are consistent
with previously published sources and the results demon-
strate the importance of smoking cessation efforts to pre-
vent deaths from smoking within Europe.
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OBJECTIVE: To determine the effectiveness and cost-
effectiveness of antimicrobial agents in the management
of chronic wounds.
METHODS: A systematic review of the literature was
undertaken. Eighteen electronic databases, relevant jour-
nals, conference proceedings and bibliographies of re-
trieved papers were searched, and an expert panel was
consulted. Randomised and non-randomized trials, with
patients, limbs, or lesions as the units of allocation were
selected. People with diabetic foot ulcers, pressure ulcers,
leg ulcers, pilonidal sinus, non-healing surgical wounds,
chronic cavity wounds, and those at risk of developing
pressure ulcers were included. Any systemic or topical
agents with antimicrobial properties were considered.
The primary outcome was wound healing (incidence of
new lesions for prevention studies) assessed with an ob-
jective measurement. All included studies were assessed
against a comprehensive checklist for methodological qual-
ity. A narrative (qualitative) overview was conducted, with
results grouped according to wound type. It was not pos-
sible to combine results by meta-analysis due to lack of
similarity across the studies.
RESULTS: Twenty-seven trials were included, 23 of ran-
domized design. There were 9 evaluations of systemic an-
timicrobials and 18 of topical agents. Several method-
ological problems were detected, the most common being
inadequate sample size. Results do not support the rou-
tine use of systemic antibiotics for leg ulcers (various eti-
ologies) or diabetic foot ulcers without acute infection,
however they may be useful as an adjunct to surgery for
pilonidal sinus. Several topical preparations may be help-
ful, including dimethyl sulfoxide, silver sulphadiazine,
benzoyl peroxide, oxyquinoline, and gentamicin. Hydro-
gels, hydrocolloids, and silastic foam dressings appear to
produce equivalence in terms of clinical effectiveness ver-
sus antimicrobial agents, and may be associated with cost
savings.
CONCLUSIONS: Most of this research requires replica-
tion in larger, well-designed studies to establish both clin-
ical and cost-effectiveness.
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OBJECTIVE: To analyze the cost-effectiveness of com-
bined hepatitis A and B vaccination (Vacc AB) and hepa-
titis B monovaccination (Vacc B) in children and adoles-
cents.
METHODS: A decision tree combined with a Markov-
model was used to predict clinical and economic outcomes
for three different age groups: 0–15, 1–15, and 11–15
years. The model was designed to follow an initially vacci-
nated age group over 30 years. The analysis took the per-
spective of society, i.e., direct and indirect costs were con-
sidered. Costs were discounted at 5% per year. Primary
outcomes measure was the incremental cost per avoided in-
fection of each vaccination strategy compared to no vacci-
nation.
RESULTS: The analysis indicated that for both Switzer-
land and Austria, Vacc AB is more cost-effective than
Vacc B in all three compared age groups. The incremental
cost-effectiveness ratios of the Vacc AB strategy for Swit-
zerland ranged from CHF 11,070 to 12,210 (Austria ATS
61,260 to 70,270) versus CHF 24,630 to 26,520 (Austria
ATS 141,750 to 159,140) for Vacc B depending on the
age group. For both vaccination strategies, the most favor-
able cost-effectiveness ratio was obtained when vaccinating
11–15 year olds. The superior cost-effectiveness of the Vacc
AB strategy is due to a reduction in hepatitis A coupled
with a modest increase in vaccination costs. In view of evi-
dence suggesting that hepatitis A and B cases are more fre-
quent than officially reported, these results are likely to be
conservative.
CONCLUSIONS: Prevention of both hepatitis A and B as
compared to hepatitis B alone is cost-effective in Switzer-
land and Austria. When taking into consideration the low
incidence of hepatitis A in both countries, combined hepati-
tis A and B vaccination is likely to have even greater impact
in countries with a higher incidence of hepatitis A infection.
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